Results 11 to 20 of about 11,011 (206)
Formoterol in the management of chronic obstructive pulmonary disease
International Journal of COPD, 2008 Paschalis Steiropoulos, Argyris Tzouvelekis, Demosthenes BourosDepartment of Pneumonology, University Hospital of Alexandroupolis, GreeceAbstract: Bronchodilators represent the hallmark of symptomatic treatment of Chronic Obstructive Pulmonary Disease ...
Paschalis Steiropoulos +2 more
doaj +1 more source
Worsening Asthma Outcomes in Australian Adults: A Comparison of Stratified Sample Surveys in 2012 and 2021. [PDF]
Med J AustABSTRACT Objectives To report patterns of asthma control, medications and healthcare utilisation in Australian adults with asthma in 2021, and assess changes since a similar survey in 2012. Study Type Cross‐sectional web‐based survey (February–March 2021; n = 5427), compared with a similar 2012 survey (n = 2686). Setting/Participants Adults (≥ 18 years)
Reddel HK +6 more
europepmc +2 more sources
Early initiation of inhaled corticosteroid-long-acting β<sub>2</sub>-agonist therapy and reduction of severe asthma exacerbations in high-risk preschool children: A longitudinal real-world cohort study. [PDF]
Pediatr Allergy ImmunolAbstract Background Evidence supporting inhaled corticosteroid plus long‐acting β2‐agonist (ICS + LABA) therapy in preschool children with asthma remains limited, and guideline recommendations remain cautious. However, real‐world effectiveness in high‐risk young children has not been adequately characterized. Objective To evaluate short‐ and long‐term
Owora AH, Jiang B, Shah Y.
europepmc +2 more sources
Regular treatment with formoterol for chronic asthma: serious adverse events [PDF]
, 2012 Epidemiological evidence has suggested a link between beta(2)-agonists and increases in asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe ...
Christopher J Cates +3 more
core +2 more sources
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events [PDF]
, 2012 An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews.ObjectivesWe set out to compare the risks of mortality and non-fatal serious adverse events in ...
Christopher J Cates +3 more
core +1 more source
Respiratory Research, 2012 Background Increased pulmonary arterial vascular smooth muscle (PAVSM) cell proliferation is a key pathophysiological component of pulmonary vascular remodeling in pulmonary arterial hypertension (PH).
Goncharova Elena A +3 more
doaj +1 more source
Scientific Reports, 2017 Mitochondrial dysfunction is associated with numerous acute and chronic degenerative diseases. The beta-2 adrenergic receptor (β2AR) agonist formoterol induces mitochondrial biogenesis (MB), but other β2AR agonists, such as clenbuterol, do not. We sought
Robert B. Cameron +3 more
doaj +1 more source
European Journal of Medical Research, 2009 Objective Immunophilin FKBP51 assists polypeptide folding, participates in glucocorticoid actions and may play a role in glucocorticoid resistance. FKBP51 is altered in patients with asthma, but its role in chronic obstructive pulmonary disease (COPD ...
Holownia A +4 more
doaj +1 more source
Respiratory Research, 2009 Background Oral corticosteroids and inhaled bronchodilators with or without antibiotics represent standard treatment of COPD exacerbations of moderate severity. Frequent courses of oral steroids may be a safety issue.
Andersson Eva +5 more
doaj +1 more source